Effect of Pioglitazone and Clobetasol

Phase 3

Recruiting

• Conditions: lichen planopilaris.; Lichen planopilaris; L66.1

• Registration Number: IRCT20210926052596N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

All patients between 15-70 years old with lichen planopilaris
localized disease in which there was no need for systemic immunosuppressors
no pregnancy or history of OCP consumption
the patient a new case or was a known case who did not receive medication during the las three months
no history of consuming a drug interaction with Pioglitazone
no contraindication for Pioglitazone consumption such as diabetes mellitus, heart failure, hypersensitivity reaction to Pioglitazone
Assign written informed consent

Exclusion Criteria

Unwillingness to participate
pioglitazone contraindications (diabetes, heart failure, COPD, kidney or liver disease, diabetes, allergy to pioglitazone)
pregnancy or OCP use
progressive multifocal disease ( that is a candidate for systemic or immunosuppressive treatment)
known case of LPP and a history of drug use in the past three months
taking drugs interacting with pioglitazone.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of lichen planopilaris based on lichen palonopilaris activity index. Timepoint: assessing the disease severity before starting the intervention and 2,4, 6 month after starting the medications. Method of measurement: Lichen planopilaris activity index.